Compare IRIX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRIX | NCEL |
|---|---|---|
| Founded | 1989 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 20.7M |
| IPO Year | 1996 | N/A |
| Metric | IRIX | NCEL |
|---|---|---|
| Price | $1.14 | $1.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 86.5K | ★ 90.6K |
| Earning Date | 11-11-2025 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,647,000.00 | N/A |
| Revenue This Year | $9.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.58 | N/A |
| 52 Week Low | $0.78 | $1.89 |
| 52 Week High | $1.87 | $7.64 |
| Indicator | IRIX | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | N/A |
| Support Level | $1.10 | N/A |
| Resistance Level | $1.24 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 63.08 | 0.00 |
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.